GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Orthopaedics Inc (NAS:MGRM) » Definitions » Debt-to-EBITDA

Monogram Orthopaedics (Monogram Orthopaedics) Debt-to-EBITDA : -0.03 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Monogram Orthopaedics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Monogram Orthopaedics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.13 Mil. Monogram Orthopaedics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.36 Mil. Monogram Orthopaedics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-15.09 Mil. Monogram Orthopaedics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Monogram Orthopaedics's Debt-to-EBITDA or its related term are showing as below:

MGRM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.48   Med: -0.06   Max: -0.02
Current: -0.03

During the past 7 years, the highest Debt-to-EBITDA Ratio of Monogram Orthopaedics was -0.02. The lowest was -3.48. And the median was -0.06.

MGRM's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs MGRM: -0.03

Monogram Orthopaedics Debt-to-EBITDA Historical Data

The historical data trend for Monogram Orthopaedics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Orthopaedics Debt-to-EBITDA Chart

Monogram Orthopaedics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -1.30 -0.02 -0.02 -0.06 -0.03

Monogram Orthopaedics Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.04 -0.02 -0.04 -0.03

Competitive Comparison of Monogram Orthopaedics's Debt-to-EBITDA

For the Medical Devices subindustry, Monogram Orthopaedics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monogram Orthopaedics's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monogram Orthopaedics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Monogram Orthopaedics's Debt-to-EBITDA falls into.



Monogram Orthopaedics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Monogram Orthopaedics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.128 + 0.364) / -16.856
=-0.03

Monogram Orthopaedics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.128 + 0.364) / -15.088
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Monogram Orthopaedics  (NAS:MGRM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Monogram Orthopaedics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Monogram Orthopaedics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Monogram Orthopaedics (Monogram Orthopaedics) Business Description

Traded in Other Exchanges
Address
3913 Todd Lane, Suite 307, Austin, TX, USA, 78744
Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Executives
Paul H Riss director
Noel Knape officer: Chief Financial Officer 3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson director, 10 percent owner, officer: Chief Executive Officer 3913 TODD LANE, AUSTIN TX 78744
Noel Goddard director 3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei officer: Chief Technology Officer 3913 TODD LANE, AUSTIN TX 78744
Douglas Unis director 3913 TODD LANE, AUSTIN TX 78744